TTY Biopharm Company Limited (TPEX:4105)
Taiwan · Delayed Price · Currency is TWD 75.40
+0.90 (1.21%)
May 8, 2026, 1:30 PM CST
TTY Biopharm Company Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 1,611 | 1,559 | 1,450 | 1,129 | 1,094 | 831.89 |
Depreciation & Amortization | 195.24 | 188.1 | 194.26 | 193.1 | 180.69 | 162.79 |
Other Amortization | 8.48 | 8.48 | 8.09 | 7.8 | 5.59 | 4.49 |
Loss (Gain) From Sale of Assets | 1.91 | 1.8 | 0.95 | 1.93 | 3.28 | 0.74 |
Asset Writedown & Restructuring Costs | 18.18 | 18.18 | 6.8 | 116.18 | 0.73 | 4.15 |
Loss (Gain) From Sale of Investments | - | -0.95 | - | 8.79 | - | 0.21 |
Loss (Gain) on Equity Investments | -178.38 | -164.87 | -400.05 | -131.34 | -116.38 | -135.18 |
Provision & Write-off of Bad Debts | -0.38 | 0.9 | 1.36 | -1.93 | 3.56 | 13.58 |
Other Operating Activities | 387.52 | 383.19 | 202.01 | 122.02 | 110.34 | 110.24 |
Change in Accounts Receivable | -80.96 | -167.14 | 35.07 | -116.16 | -95.4 | -114.32 |
Change in Inventory | -197.38 | -119.08 | -161.27 | -56.75 | -83.95 | 155.12 |
Change in Accounts Payable | 148.28 | -13.34 | -10.21 | 11.95 | 96.01 | -23.07 |
Change in Unearned Revenue | -4.05 | 19.37 | 20.11 | -18.89 | -6.64 | 23.48 |
Change in Other Net Operating Assets | 109.58 | 48.08 | 2.63 | -179.89 | 43.55 | 222.24 |
Operating Cash Flow | 2,019 | 1,762 | 1,349 | 1,085 | 1,236 | 1,256 |
Operating Cash Flow Growth | 44.61% | 30.57% | 24.33% | -12.17% | -1.64% | 138.69% |
Capital Expenditures | -112.98 | -94.61 | -125.16 | -78.35 | -91.52 | -60.32 |
Sale of Property, Plant & Equipment | 0.09 | 1.13 | 3.93 | 7.01 | 9.39 | 0.03 |
Cash Acquisitions | - | - | -242.87 | - | - | - |
Sale (Purchase) of Intangibles | -124.76 | -56.22 | -9.14 | -21.23 | -43.98 | -13.84 |
Investment in Securities | -120.95 | -170.89 | 128.18 | 168.55 | 34.68 | -14.1 |
Other Investing Activities | -71.2 | -46.78 | 1.49 | -78.62 | -41.7 | -80.56 |
Investing Cash Flow | -431.28 | -367.36 | -243.56 | -2.63 | -133.14 | -168.78 |
Short-Term Debt Issued | - | 6,300 | 8,050 | 10,280 | 10,890 | 5,400 |
Long-Term Debt Issued | - | 400 | 500 | 400 | 430 | - |
Total Debt Issued | 5,350 | 6,700 | 8,550 | 10,680 | 11,320 | 5,400 |
Short-Term Debt Repaid | - | -6,800 | -8,300 | -10,200 | -11,231 | -5,404 |
Long-Term Debt Repaid | - | -408.61 | -409.77 | -434.17 | -421.55 | -16.54 |
Total Debt Repaid | -5,859 | -7,209 | -8,710 | -10,634 | -11,653 | -5,421 |
Net Debt Issued (Repaid) | -508.93 | -508.61 | -159.77 | 45.83 | -332.62 | -20.54 |
Common Dividends Paid | -1,044 | -1,044 | -870.28 | -845.41 | -745.95 | -994.6 |
Other Financing Activities | -40.26 | -40.27 | -21.19 | -16.75 | -24.83 | -28.99 |
Financing Cash Flow | -1,594 | -1,593 | -1,051 | -816.33 | -1,103 | -1,044 |
Foreign Exchange Rate Adjustments | -44.3 | -53.03 | 97.02 | -2.66 | 135.85 | -44.91 |
Net Cash Flow | -49.97 | -251.77 | 151.6 | 263.7 | 135.07 | -1.48 |
Free Cash Flow | 1,906 | 1,667 | 1,224 | 1,007 | 1,144 | 1,196 |
Free Cash Flow Growth | 48.35% | 36.19% | 21.57% | -12.00% | -4.33% | 233.86% |
Free Cash Flow Margin | 29.26% | 25.84% | 20.77% | 18.29% | 22.61% | 26.37% |
Free Cash Flow Per Share | 7.27 | 6.69 | 4.91 | 4.04 | 4.59 | 4.80 |
Cash Interest Paid | 38.41 | 38.41 | 38.46 | 34.99 | 23.22 | 18.67 |
Cash Income Tax Paid | 371.76 | 371.76 | 297.06 | 283.71 | 277.92 | 220.22 |
Levered Free Cash Flow | 1,240 | 948.22 | 891.34 | 737.63 | 806.96 | 980.02 |
Unlevered Free Cash Flow | 1,262 | 971.94 | 915.25 | 759.62 | 821.24 | 991.87 |
Change in Working Capital | -24.53 | -232.12 | -113.67 | -359.75 | -46.44 | 263.45 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.